Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Ardelyx Is Soaring Today

TheMotleyFool

0 0

Why Ardelyx Is Soaring TodayPhoto, wide shot, wide-angle lens, Medical device manufacturer, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/3a7f6312-1eee-4702-9005-93cc1e62f970.png

After upbeat results from a Phase 3 trial, shares of Ardelyx (NASDAQ: ARDX), a clinical-stage biotech focused on cardiorenal disease, rose as much as 23% in early-morning trading on Tuesday. Shares were up about 16% as of 10:37 a.m. EDT.

Ardelyx reported positive results from its Phase 3 AMPLIFY study today. This trial was designed to test its experimental drug tenapanor in combination with phosphate binders as a hopeful treatment for patients with chronic kidney disease who are on dialysis.

Here are the key takeaways from the study:

Source Fool.com

Like: 0

ARDX

Share